PDL241 is a novel humanized monoclonal antibody to the CS1 glycoprotein that we believe may have potential in immunologic diseases. We are currently conducting preclinical toxicology and IND-enabling studies for this lead preclinical candidate, which we hope to advance into the clinic.  Under the terms of our collaboration agreement with BMS to develop elotuzumab, BMS has an option to expand the collaboration to include the PDL241 antibody upon completion of certain pre-agreed preclinical studies.

Elotuzumab Targets CS1
Publications About CS1